NovaBay Pharmaceuticals, Inc. (NYSE:NBY) shares are trading higher after the company announced third-party testing results showing that its Avenova formulation kills SARS-CoV-2. The company intends to submit test results to the EPA for approval.
"Since Avenova's inception, we have known it to be a powerful antimicrobial spray solution, effective against all types of pathogens, including a wide variety of viruses, bacteria, and fungi. Now we have results from a highly reputable independent laboratory confirming Avenova kills the coronavirus that causes COVID-19," said Justin Hall, NovaBay CEO.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Avenova is available without a prescription on Amazon and on Avenova.com.
NovaBay is a biopharmaceutical company that develops, manufactures, and markets anti-infective products for a multitude of uses.
NovaBay's stock was trading up 62.25% at $1.83 per share on Monday at the time of publication. The company has a 52-week high of $1.94 and a 52-week low of $0.24.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.